Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-85738 in Advanced Solid Tumors With RAS Mutations
NCT07746141Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 2
01
Overview
Phase 1, open-label trial of BG-85738 in solid tumor (4 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events, Number of Participants with Dose Limiting Toxicity and 4 more. Started Sep 2026; status: recruiting.
02
Drugs
BG-85738
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07746141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746141.